About Us
Revolutionary Company with Revolutionary Therapies.

Our Krewe
We are on a mission to change the lives of people with autoimmune and allergic diseases by developing therapies that reset the immune system to achieve long-term disease remission. Revolo Biotherapeutics (“Revolo Bio”) has a global footprint, with headquarters in both New Orleans, LA, in the US, and London in the United Kingdom.
Our team of accomplished industry professionals has a track record of success in funding and executing drug development and commercialization plans. We are ready to revolutionize autoimmune and allergic disease treatment!
Management



Jonathan Rigby, mba
Group Chief Executive Officer



Jonathan Gold
Chief Financial Officer



Jones W Bryan, ph.d.
President & Chief Business Officer



Dr. Roly Foulkes
Chief Scientific Officer



Nancy Vinh
SVP of Clinical Operations



Beth Alley
VP of Regulatory Affairs



Marylyn Rigby
SVP of Marketing & Investor Relations
Board of Directors


Peter Greenleaf
Chairman


Jonathan Rigby
Group Chief Executive Officer


Dr. Isaac Cheng
Non-Executive Director


Michael Albisser
Non-Executive Director


Marla S. Persky
Non-Executive Director


Glen Giovanetti
Non-Executive Director

